Lexaria Bioscience (LEXX) Operating Margin (2017 - 2026)
Lexaria Bioscience (LEXX) posted Operating Margin of 7259.52% for Q1 2026, down 369.82% sequentially from 1545.17% in Q3 2025, and down 567847.0% YoY from N/an in Q1 2025.
Lexaria Bioscience (LEXX) Operating Margin (2017 - 2026) Analysis & Trends
Lexaria Bioscience has reported Operating Margin for 10 years, with the latest figure at 7259.52% in Q1 2026.
- Quarterly Operating Margin fell 567847.0% year-over-year to 7259.52% in Q1 2026, while the trailing twelve-month figure through May 2026 was 3973.16% (down 212306.0% YoY) and the FY2025 annual result came in at 1683.01%, down 44385.0% from the prior year.
- Operating Margin slipped to 7259.52% in Q1 2026 per LEXX's latest filing, from 1545.17% in the prior quarter.
- Over five years, Operating Margin peaked at 460.69% in Q1 2024 and troughed at 7259.52% in Q1 2026.
- A 5-year average of 2674.94% and a median of 2115.16% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2026: Operating Margin soared 1269960 bps in 2022, then slumped 567847 bps in 2026.
- Over 5 years, Operating Margin stood at 1734.71% in 2022, then surged by 57 bps to 753.01% in 2023, then sank by 94 bps to 1462.95% in 2024, then decreased by 6 bps to 1545.17% in 2025, then plunged by 370 bps to 7259.52% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 7259.52%, 1545.17%, and 2155.41% for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 19.75% |
| 10 | Lexaria Bioscience | 10.31 Mn | 6.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -7,259.52% |
| Aug 31, 2025 | -1,545.17% |
| May 31, 2025 | -2,155.41% |
| Feb 28, 2025 | -1,581.04% |
| Nov 30, 2024 | -1,462.95% |
| Aug 31, 2024 | -2,622.70% |
| May 31, 2024 | -2,074.90% |
| Feb 29, 2024 | -460.69% |
| Nov 30, 2023 | -753.01% |
| Aug 31, 2023 | -3,624.19% |
| May 31, 2023 | -3,089.64% |
| Feb 28, 2023 | -6,609.86% |
| Nov 30, 2022 | -1,734.71% |
| Aug 31, 2022 | -673.46% |
| May 31, 2022 | -2,425.20% |
| Feb 28, 2022 | -4,726.50% |
| Nov 30, 2021 | -14,434.31% |
| Aug 31, 2021 | -4,199.30% |
| May 31, 2021 | -1,257.77% |
| Feb 28, 2021 | -575.25% |